SGN-LIV1A: a development stage antibody drug-conjugate targeting LIV-1 for the treatment of metastatic breast cancer.

被引：3
|
作者：
Sussman, Django [1 ]
Smith, Leia M. [1 ]
Anderson, Martha E. [1 ]
Duniho, Steve [1 ]
Hunter, Joshua H. [1 ]
Kostner, Heather [1 ]
Miyamoto, Jamie B. [1 ]
Nesterova, Albina [1 ]
Westendorf, Lori [1 ]
Van Epps, Heather A. [1 ]
Whiting, Nancy [1 ]
Benjamin, Dennis R. [1 ]
机构：
[1] Seattle Genet, Bothell, WA USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-3962
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3962
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Development of a CUB domain-containing protein 1 (CDCP1)-targeting antibody-drug conjugate for triple-negative and metastatic breast cancer
    Gough, Madeline
    Kwah, Kayden
    He, Yaowu
    Snell, Cameron Edward
    Hooper, John D.
    Kryza, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Targeting trastuzumab and TDM-1 resistant breast cancer cells with EV20/MMAF, an antibody drug-conjugate against HER3
    Sala, Gianluca
    Gandullo, Lucia
    Capone, Emily
    Elena Diaz-Rodriguez, Maria
    D'Agostino, Daniela
    De Laurenzi, Vincenzo
    Sauniere, Jean-Frederic
    Iacobelli, Stefano
    Pandiella, Atanasio
    CANCER RESEARCH, 2018, 78 (13)
  • [33] Development of novel MUC1-C targeting antibody-drug conjugate for pancreatic cancer treatment
    Ahmad, Rehan
    Panchamoorthy, Govind
    Raina, Deepak
    Lawney, Brian
    Kharbanda, Surender
    Jasuja, Ravi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Antibody-drug conjugates in metastatic breast cancer. A promising treatment strategy
    Schroeder, Maria
    Schmidt, Marcus
    Marme, Frederik
    ONKOLOGIE, 2024, 30 (06): : 479 - 484
  • [35] SDP03923-000-9106, a novel and optimized LIV-1 ADC with superior anti-tumor efficacy in breast cancer xenograft models
    Gong, Yanling
    Sun, Xing
    Yang, Changyong
    Chen, Simeng
    Zhang, Wei
    Liao, Cheng
    CANCER RESEARCH, 2024, 84 (06)
  • [36] LIV-1 regulates zinc uptake and E-cadherin (CDH1) expression in MDA-MB-231 breast cancer cells but does not influence SNAI1
    Chong, Leelyn
    Sankavaram, Kavitha
    Freake, Hedley C.
    FASEB JOURNAL, 2011, 25
  • [37] Development of AGS15E, a novel antibody drug conjugate targeting SLITRK6 for the treatment of bladder cancer.
    Morrison, Kendall
    CANCER RESEARCH, 2013, 73 (08)
  • [38] LIV-1 breast cancer protein belongs to new family of histidine-rich membrane proteins with potential to control intracellular Zn2+ homeostasis
    Taylor, KM
    IUBMB LIFE, 2000, 49 (04) : 249 - 253
  • [39] Development of an antibody-drug conjugate targeting TIM-1 for the treatment of ovarian and renal cell carcinoma
    Thomas, Lawrence J.
    Vitale, Laura
    O'Neill, Thomas
    Dolnick, Ree
    Wallace, Paul K.
    Minderman, Hans
    Gergel, Lauren E.
    Forsberg, Eric M.
    Boyer, James M.
    Storey, James R.
    Hammond, Russell A.
    Widger, Jennifer
    Sundarapandiyan, Karuna
    Crocker, Andrea
    Marsh, Henry C.
    Keler, Tibor
    CANCER RESEARCH, 2014, 74 (19)
  • [40] Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
    Rassy, Elie
    Rached, Layal
    Pistilli, Barbara
    BREAST, 2022, 66 : 217 - 226
12345